{"id":"NCT02756624","sponsor":"Nicox Ophthalmics, Inc.","briefTitle":"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution","officialTitle":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04","primaryCompletion":"2016-08","completion":"2016-08","firstPosted":"2016-04-29","resultsPosted":"2017-07-26","lastUpdate":"2017-09-11"},"enrollment":516,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Healthy Subjects"],"interventions":[{"type":"DRUG","name":"AC-170 0.24%","otherNames":[]},{"type":"DRUG","name":"AC-170 Vehicle","otherNames":[]}],"arms":[{"label":"AC-170 0.24%","type":"EXPERIMENTAL"},{"label":"AC-170 Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution","primaryOutcome":{"measure":"Tolerability of AC 170 0.24% at Visit 1 (Day 1)","timeFrame":"Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation","effectByArm":[{"arm":"AC-170 0.24%","deltaMin":0.87,"sd":1.435},{"arm":"AC-170 Vehicle","deltaMin":0.5,"sd":1.106}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":343},"commonTop":["Visual acuity reduced","Conjunctival hyperemia","Instillation site pain","Punctate keratitis","Instillation site erythema"]}}